Premium
Patients with active relapsing‐remitting multiple sclerosis synthesize antibodies recognizing oligodendrocyte progenitor cell surface protein: Implications for remyelination
Author(s) -
Niehaus Antje,
Shi Jian,
Grzenkowski Martina,
DiersFenger Marianne,
Archelos Juan,
Hartung HansPeter,
Toyka Klaus,
Brück Wolfgang,
Trotter Jacqueline
Publication year - 2000
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/1531-8249(200009)48:3<362::aid-ana11>3.0.co;2-6
Subject(s) - remyelination , multiple sclerosis , relapsing remitting , progenitor cell , oligodendrocyte , antibody , medicine , progenitor , immunology , neuroscience , biology , myelin , stem cell , microbiology and biotechnology , central nervous system
In multiple sclerosis (MS), remyelination of demyelinated lesions diminishes with disease progression for unknown reasons. Oligodendrocyte progenitor cells contribute to remyelination; however, antibodies specific for oligodendrocyte progenitor antigens could block remyelination by eliminating or impeding these cells. In myelinating cultures, cell lysis with antibody recognizing a progenitor cell–specific surface glycoprotein (AN2) suppressed the synthesis of myelin proteins. Cerebrospinal fluid from patients with relapsing‐remitting active MS contains antibodies against AN2, whereas cerebrospinal fluid from patients with nonactive disease does not. This is the first report describing antibodies in MS against a progenitor cell–specific antigen that may contribute to the development and progression of chronically demyelinated lesions. Ann Neurol 2000;48:362–371